Malaria parasite protein

The term "Malaria parasite protein" refers to the diverse array of proteins produced by protozoan parasites of the genus Plasmodium, which are responsible for causing malaria in humans. These proteins are essential for the parasite's survival and progression through its complex life cycle, involving stages in the liver and red blood cells of the host, as well as the midgut and salivary glands of the Anopheles mosquito (Source: Cowman et al., 2016, "The Molecular Basis of Erythrocyte Invasion by Malaria Parasites", Nature Reviews Microbiology). Key therapeutic targets within this group include enzymes like dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), which are involved in folate metabolism, and the cytochrome bc1 complex, which is vital for mitochondrial electron transport. Surface-exposed proteins, such as Merozoite Surface Protein 1 (MSP1) and Apical Membrane Antigen 1 (AMA1), are critical for the invasion of host erythrocytes and are primary targets for vaccine development. Drugs like chloroquine and artemisinin interact with various parasite processes, such as heme detoxification and redox homeostasis, to clear the infection. However, the high rate of mutation in these proteins often leads to the emergence of drug-resistant strains, posing a significant challenge to global health. Because this term describes a broad category rather than a single molecular entity, it is not a specific therapeutic target in isolation.

Other names

Plasmodium proteinMalarial antigenPlasmodium falciparum protein

Mechanisms of action are target-specific; for instance, quinolines inhibit heme detoxification, antifolates inhibit nucleic acid synthesis via dihydrofolate reductase, and artemisinins cause oxidative damage to multiple parasite proteins (Source: White, N. J., 2004, "Antimalarial drug resistance", J. Clin. Invest.).